With more than 35 years experience in the pharmaceutical industry and biotech, Philippe Goupit will lead Tollys’ plans for growth.
Bettina Werle will supervise the laboratory, help set its scientific priorities and lead Tollys’ R&D team.
Support funding for breakthrough innovation will help company’s development in preparation for clinical trials in bladder cancer
Funds will further development of a new cancer immunotherapy: synthetic TLR3 agonist TL-532.
Three senior industry executives join the board of directors.
Triggering & installing efficient anti-tumor immunity
41 quai Fulchiron
69005 Lyon, FRANCE